CPT code 81162 – BRCA1/BRCA2 genetic testing analysis

Found our content helpful?

Key takeaways

CPT code 81162 bundles BRCA1 and BRCA2 full sequencing plus duplication/deletion analysis into one Tier 1 molecular pathology code. Billing its component codes alongside it is an NCCI unbundling violation.

CPT 81211, 81213 and 81214 were deleted on January 1, 2019. A claim that still carries one of them will be rejected outright.

Medicare coverage follows the active Local Coverage Determination (LCD). Eligibility usually needs a documented personal or family history meeting HBOC risk thresholds.

Modifier 33 removes patient cost-sharing when USPSTF criteria are fully documented. Incorrect use is a compliance risk under ACA Section 2713, not just a billing error.

Pabau’s claims management software submits 81162 claims electronically through Claim.MD, checks eligibility in real time, and posts ERA remittances back against the charge.

CPT code 81162: Official descriptor and Tier 1 classification

CPT code 81162 is a Tier 1 molecular pathology code. Its official American Medical Association (AMA) descriptor has two parts:

• BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis;
• full sequence analysis and full duplication/deletion analysis (ie, detection of large gene rearrangements).

The code sits in the molecular pathology section (81105-81479) and covers germline testing only. Somatic or tumor-based BRCA analysis uses a different code set entirely.

Tier 1 classification means the AMA Editorial Panel has assigned a specific code to this analytic service. Tier 2 codes (81400-81408) work differently, using a stacked complexity-level structure. For billing purposes, Tier 1 codes like 81162 carry discrete descriptors that define which work is included in the service and which is not. That precision drives most of the unbundling exposure described below.

What CPT code 81162 covers and what it excludes

81162 covers two distinct analytic methods performed on the same specimen for both genes simultaneously. Each component is required; billing the code when only one method was performed on only one gene is a descriptor mismatch.

CPT code 81162 vs the adjacent BRCA codes: choosing the right one

The most common miscoding error is billing 81162’s component codes as a substitute for it when the lab performed the full combined analysis. Because 81162 already covers sequencing and del/dup analysis for both genes, submitting those components alongside it is an NCCI bundling violation. The reverse error is billing 81162 when only one gene or one method was performed. That is a descriptor mismatch, and it carries the same audit exposure.

Three codes that older billing guides still list are no longer valid. CPT 81211, 81213 and 81214 were deleted from the CPT code set effective January 1, 2019. The deleted 81211 covered full sequence analysis of both genes, plus common duplication/deletion variants in BRCA1 only. Its work is now split across the active component codes below.

Key rule: Use 81162 when the lab report confirms full sequencing of both BRCA1 and BRCA2 plus large rearrangement analysis. In that situation it is the only correct code. Splitting the same work across 81163 and 81164, or across the single-gene codes, is an unbundling violation under current NCCI tables.

ICD-10 diagnosis codes to pair with CPT code 81162

Claim acceptance for CPT code 81162 depends on submitting a diagnosis code that appears on the payer’s covered-indications list. The ICD-10-CM codes below represent the most widely accepted groupings across Medicare and commercial payers. Our ICD-10-CM code library carries the full official descriptor for each one. Always verify them against the active Local Coverage Determination (LCD) for your MAC jurisdiction.

The distinction between preventive and diagnostic coverage matters for patient cost-sharing. Modifier 33 signals a USPSTF Grade B preventive indication. When it is used on an 81162 claim, ACA Section 2713 requires first-dollar coverage from most commercial plans. Without modifier 33, the claim processes as a diagnostic service and standard cost-sharing applies.

Medicare coverage, LCD requirements, and eligible patient criteria

Medicare coverage for CPT code 81162 is governed by Local Coverage Determinations issued by individual Medicare Administrative Contractors (MACs). Verify the active LCD at the CMS Medicare Coverage Database before submitting claims. LCD numbering and criteria vary by jurisdiction and are revised regularly.

Common Medicare eligibility criteria appearing across active LCDs include the following. Checking the patient’s benefits before the test is ordered prevents the most common LCD-related denials.

• Personal history of breast or ovarian cancer meeting HBOC risk thresholds
• First- or second-degree relative with a known BRCA1/2 pathogenic variant
• Family history pattern consistent with hereditary breast and ovarian cancer syndrome, scored with an evidence-based risk tool (Ontario Family History Assessment Tool, Manchester Score)
• Documented pre-test genetic counseling, or a referral to a certified genetic counselor, which most MAC jurisdictions require. Verify the current active LCD
• USPSTF Grade B recommendation for BRCA risk assessment and genetic counseling for qualifying women with a family history suggestive of BRCA1/2 mutations

Medicare Advantage plans may apply additional prior authorization requirements beyond traditional Medicare LCD criteria. The CMS ICD-10 codes and coverage resources confirm that coverage determinations for molecular diagnostic tests are updated annually. Verify them against the current year’s guidance.

Prior authorization requirements for CPT code 81162

Prior authorization requirements vary significantly by payer type. No universal PA rule applies, and submitting without verifying the specific plan’s policy is one of the most preventable denial drivers for CPT code 81162.

2026 Medicare fee schedule and reimbursement rate for CPT code 81162

CPT code 81162 is reimbursed under the Medicare Clinical Laboratory Fee Schedule (CLFS), not the Physician Fee Schedule (PFS). The CLFS does not use RVU-based calculations. Rates are set through a market-pricing process under PAMA (Protecting Access to Medicare Act) and revised annually. CMS published the 2026 CLFS rates in late 2025. Verify the current national limitation amount directly from the CMS fee schedule lookup tool before billing.

Tracking payments against the CLFS rate and reconciling the electronic remittance advice is the fastest way to identify underpayments on 81162 claims. Practices that submit electronically through a clearinghouse can match each ERA remittance against the expected CLFS rate at the claim level. Lab code reimbursement differs from physician code reimbursement on four points.

• No facility vs non-facility distinction: CLFS codes have a single national rate regardless of where the specimen was collected
• Split billing is common: the ordering physician bills for the clinical encounter and risk assessment; the clinical laboratory bills 81162 under its own NPI
• Commercial rates vary: contracted lab rates often differ substantially from CLFS; confirm contract terms before assuming Medicare-equivalence
• Annual rate changes: CLFS rates are adjusted each January. Do not assume a 2025 rate applies to a 2026 claim; check the current CMS CLFS file

Modifiers for CPT code 81162 and when to use them

Three modifiers are relevant to CPT code 81162. Each has a specific trigger condition. Using the wrong one creates a billing error. Using modifier 33 without meeting the full USPSTF documentation standard creates a compliance exposure.

Documentation requirements for BRCA1/BRCA2 genetic testing billing

Documentation for CPT code 81162 claims must demonstrate medical necessity before the test is ordered, not reconstruct it after a denial. A charge-capture workflow that pre-links the ICD-10 code and captures the required documentation fields prevents the most common submission errors. Setting that expectation with ordering providers at the start saves the billing team an appeal cycle later.

• Ordering provider note: documents the clinical indication, personal or family history meeting risk criteria, and the specific test ordered
• Genetic counseling record: pre-test counseling note or certified genetic counselor attestation; required by most Medicare LCDs and commercial payers
• Risk assessment documentation: structured risk tool output (Manchester Score, BRCAPRO, Tyrer-Cuzick) or equivalent clinical narrative
• Specimen collection record: specimen type, collection date, and collection facility, which ties the lab billing to the clinical event
• Lab report: must confirm full sequence analysis and large rearrangement (del/dup) analysis on both BRCA1 and BRCA2. A report showing sequencing alone does not support billing 81162
• ICD-10 linkage: the diagnosis code must appear on the covered-indications list for the active LCD or payer policy in effect at the date of service

Submitting the 837 electronic claim file with incomplete documentation is a leading cause of medical necessity denials. Check that the ordering provider note and counseling record are retrievable before the lab submits the claim. The seven checkpoints below map each one to the denial it prevents.

Top reasons CPT 81162 claims are denied and how to appeal

Most 81162 denials are preventable, and the patterns below appear consistently across payers. Effective denial management for molecular pathology claims starts with matching the denial code to its root cause. The wrong appeal approach wastes time and appeal cycles, because sending clinical literature will not fix a missing PA number. Tracking denial codes at the CPT code level reveals which payer is generating recurring patterns.

Review your compliance standards for genetic testing once a year. Payer LCD updates and NCCI table revisions shift which denial patterns appear most often, even when your billing practices stay the same.

Billing CPT 81162 with companion codes: Genetic counseling and panel codes

Several companion codes interact with CPT code 81162 on the same claim or on the same date of service. The rules differ by code type.

Genetic counseling codes (96040, 99401-99404): These can be billed on the same date as 81162 when counseling is genuinely provided as a separate, documented service. The counseling code is typically billed by the ordering provider or a certified genetic counselor under their own NPI, not by the laboratory billing 81162. A clean claim requires that the counseling note and the lab order appear as distinct services with different performing providers where applicable.

Hereditary cancer panel codes (81432, 81433): These multi-gene panel codes include BRCA1 and BRCA2 analysis among a broader gene set. If a comprehensive hereditary cancer panel was ordered, do not bill 81162 separately alongside 81432 or 81433 for the BRCA components. That is another form of unbundling.

NCCI edit interactions: NCCI edits for molecular pathology codes are updated quarterly. 81162 pairs as column 1 against its active component codes, among them 81163, 81164, 81165 and 81216. Modifier 59 will not resolve that edit where 81162 is the correct comprehensive code. Check the current NCCI tables before attempting to override a bundling edit with a modifier.

How Pabau keeps CPT 81162 claims documented and paid

Genetic testing billing splits across two entities, and standard practice management workflows are rarely configured for it by default. The ordering practice captures the clinical encounter. The reference laboratory captures the test itself. When these two billing events are not coordinated, the lab’s claim goes out without documentation that already exists in the practice’s record.

Pabau, a practice management platform built for healthcare practices, submits 81162 claims electronically through the Claim.MD clearinghouse. Its claims management software checks patient eligibility in real time before the test is ordered, then tracks each claim’s status after submission. ERA remittances post back against the original charge, so an underpayment or a denial is visible without a separate reconciliation step.

For practices using Pabau alongside a reference lab, one habit pays for itself. Treat the genetic counseling note as a required field in the ordering encounter, rather than a document to chase after a denial arrives.

Streamline genetic testing billing from order to payment

Pabau submits claims electronically through Claim.MD, checks patient eligibility in real time, and posts ERA remittances back automatically. Billing teams can follow an 81162 claim without switching systems.

Book a demo

Conclusion

CPT code 81162 is a precise code for a complete service: BRCA1 and BRCA2 full sequencing plus large rearrangement analysis in one billable event. The two most costly errors are splitting the test into component codes, which NCCI treats as unbundling, and submitting without the documentation payers require. Billing a deleted code such as 81211 is the third.

Pabau’s claims management tools submit 81162 claims electronically, verify patient eligibility in real time, and track each claim’s status through to the ERA. Book a demo to see how a genetic testing claim moves from the order to the posted remittance.

Continue your research

Need to understand how clearinghouse submissions work for lab codes? Medical claims clearinghouse guide explains how electronic submissions route from the billing system to the payer.

Not sure which payer policies apply to your lab claims? Getting credentialed with insurance companies covers payer enrollment steps that affect which LCDs apply to your claims.

Looking for coding references across related billing codes? CPT billing code reference guides on Pabau cover procedure coding across multiple specialty areas.

Frequently asked questions